Therapies to defeat infectious diseases and treat Inflammatory conditions
Company focused on the development and commercialization anti-infective lipid and protein therapeutics
- The company is a biopharmaceutical company focused on the development and commercialization of first in class of a new class of novel and groundbreaking anti-infective lipid and protein therapeutics for the treatment and prevention of a variety of infectious diseases and inflammatory conditions.
- The company is seeking $4 Million financing at $12 Million pre-money to be used to proceeds for the completion of IND enabling studies & initiation of Phase-1 clinical trials.
- The company's lead lipid drug CT-02 has been shown to be effective against SARS- CoV-2, RSV, (H1N1)pdm09 and Rhinoviruses with a single therapeutic agent.
- The company’s drug is also a potent anti-inflammatory at the same time.
- The company’s drug is naturally present on our lung surface and has been shown to be very safe in multiple animal species.
- The company’s drug has the potential for prophylaxis and intervention against a variety of respiratory viruses.
- The company’s therapeutic is able to treat multiple viral infections at the same time.
- The company’s new therapeutics are very broad spectrum, safe and effective therapeutics under development.
- The company has exceptional team of leading experts in the fields of Innate Immunology, Bioengineering, Protein & Lipid Chemistry, Pharmacology, Biophysics, infectious diseases that has a proven track record of identifying, patenting, and developing products and technologies for diseases affecting millions of people world-wide.
- Raised $610,000 to date.
Gezondheidszorg & farmacie
Brookz 500: bestel jouw exemplaar!
Unieke 'Who is Who' van de Nederlandse overnamemarkt. Alle actieve (overname)advieskantoren, investeringsmaatschappijen en advocatenkantoren in één waardevolle uitgave van 252 pagina's (t.w.v. €24,95)! Bestel nu!